All study participants received remdezivir, a drug from Gilead Sciences that had previously been shown to reduce recovery time, defined as good enough to leave the hospital, by an average of four days. Those who were also given baricitinib recovered one day earlier than those who received only remdezivir, Lily said.
Lily said she plans to discuss with regulators the possible emergency use of baricitinib for hospitalized patients with Covid-19.
If approved, Lilly will offer the drug to be sold by the usual commercial means. Based on current prices, the government will pay $ 105 per patient per day, and for people with private insurance, hospitals will pay about $ 1
It would be important to know how many study participants also received steroid medications, which other studies show reduce the risk of death for seriously ill, hospitalized patients with Covid-19, said Dr. Jesse Goodman, former US Food and Drug Administration and the drug chief scientist, who is now at Georgetown University, who has no role in the study.
Let’s figure out how best to use the various drugs that have been shown to be “something we will have to work on,” he said.